Merck to buy cancer drug developer Peloton Therapeutics for $1.05 billion in cash
Merck Inc's lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.
New Delhi: Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.
The company's lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.
Peloton shareholders will be eligible to receive a further $1.15 billion on achieving certain milestones.
Read Also: Merck will now be called Procter & Gamble Health
The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week.
Credit Suisse acted as a financial adviser for Merck and Covington & Burling LLP as its legal adviser. Centerview Partners was a financial adviser to Peloton and Wilson Sonsini Goodrich & Rosati was its legal adviser.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd